04467nam 2200709 450 991071735530332120221105201948.0(CKB)4330000000505680(NjHacI)994330000000505680(CaOOCEL)10063317(OCoLC)897023740(OCoLC)1117910941(OCoLC)1000916263(VaAlCD)20.500.12592/22ntq3(EXLCZ)99433000000050568010063317CaOOCEL(Public Documents)20221105d2013 uy 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierScreening pelvic examinations in asymptomatic average risk adult women /Andrew Olson [and six others] editorsWashington (DC) :Canadian Task Force on Preventive Health Care,[2013]©20131 online resource (iii, 50 pages) illustrations"Evidence-based synthesis program.""September 2013."Includes bibliographical references.The routine pelvic examination has been a usual part of preventive care for women for many decades. In 2008, 63.4 million pelvic examinations were performed in the United States. Many women and providers believe that the routine pelvic exam should be included in an annual comprehensive well-woman visit.^The exam consists of inspection of the external genitalia, speculum examination of the vagina and cervix, bimanual examination, and sometimes rectal or rectovaginal examination.^Traditionally, the examination in the asymptomatic average risk women has been used to screen for pathology through palpation, visualization, and specimen collection.^Pathology potentially detectable on the pelvic examination includes malignancies (e.g., cervical, ovarian, uterine, bladder, vaginal or vulvar); infections (e.g., Chlamydia, gonorrhea, warts, candidiasis, bacterial vaginosis); pelvic inflammatory disease (PID); or other pathology (e.g., atrophic vaginitis, cervical polyps, uterine prolapse, fibroids). In addition, pelvic examinations are often performed prior to the provision of hormonal contraception.^Recent high quality evidence-based reviews and guidelines have concluded that pelvic examinations are not required for Chlamydia and gonorrhea screening or for hormonal contraception initiation and up-to-date evidence-based guidelines for cervical cancer screening are also available.^However, we are unaware of any systematic reviews that have investigated the utility of the pelvic examination for the other indications.^This systematic review was undertaken to evaluate the benefits and harms of the routine screening pelvic examination in asymptomatic, average risk, non-pregnant, adult women. For cervical cancer and sexually transmitted infection (i.e., Chlamydia and gonorrhea) screening and for initiation of hormonal contraception we summarize the results of recent reviews and guidelines from major US health organizations. For all other indications, we performed and report results from a comprehensive search of the medical literature.Ca-125IptcncCancerIptcncCancer screeningIptcncCervical cancerIptcncCervical screeningIptcncCervixIptcncChlamydia infectionIptcncClinical medicineIptcncEvidence-based medicineIptcncGonorrheaIptcncCa-125CancerCancer screeningCervical cancerCervical screeningCervixChlamydia infectionClinical medicineEvidence-based medicineGonorrhea618.1Bloomfield Hanna E.1353456Olson AndrewUnited States.Department of Veterans Affairs.Health Services Research and Development Service,Quality Enhancement Research Initiative (U.S.)Minneapolis VA Health Care System (U.S.).VA Evidence Synthesis Program.Evidence-based Synthesis Program (U.S.)NjHacINjHaclBOOK9910717355303321Screening pelvic examinations in asymptomatic average risk adult women3498643UNINA